Annals of SBV

Register      Login

VOLUME 9 , ISSUE 2 ( July-December, 2020 ) > List of Articles


Microcytic Anemia: A Brief Overview

Tungki Pratama Umar

Citation Information : Umar TP. Microcytic Anemia: A Brief Overview. 2020; 9 (2):42-47.

DOI: 10.5005/jp-journals-10085-8126

License: CC BY-NC 4.0

Published Online: 01-12-2020

Copyright Statement:  Copyright © 2020; The Author(s).


Microcytic anemia is caused by hemoglobin (Hb) deficiency synthesis in erythroid precursors, leading to reduced mean corpuscular volume (MCV) of red blood cells. It is the most common type of anemia, primarily due to iron deficiency, followed by chronic disease, and thalassemia. Diagnosis of the spectrum of microcytic anemia requires an adequate history taking and physical examination to search for specific indicators of each disease with a further investigation as indicated for a definitive diagnosis. The treatment of microcytic anemia varies depending on the cause of the disease. The prognosis of the disease also varies depending on the factors underlying the anemia condition.

  1. Camaschella C. How I manage patients with atypical microcytic anaemia. Br J Haematol 2013;160(1):12–24. DOI: 10.1111/bjh.12081.
  2. Matos JF, Dusse LMS, Borges KBG, de Castro RLV, Coura-Vital W, Carvalho MG. A new index to discriminate between iron deficiency anemia and thalassemia trait. Rev Bras Hematol Hemoter 2016;38(3):214–219. DOI: 10.1016/j.bjhh.2016.05.011.
  3. Chaudhry HS, Kasarla MR. Microcytic Hypochromic Anemia [Internet]. StatPearls Publishing; 2020. [cited 2020 Jul 11]. Available from:
  4. Lembar S, Dony Y, Aprilia A, Tjahyadi CA. Buku Saku Hematologi: Eritrosit dan Kelainannya Jilid I. 1st ed., Jakarta: Universitas Katolik Indonesia Atma Jaya; 2015.
  5. Rocha ÉMB, Lopes AF, Pereira SM, Leone C, Abreu LC, Vieira PD, et al. Iron deficiencyy anemia and its relationship with socioeconomic vulnerability. Rev Paul Pediatr 2020;38:e2019031. DOI: 10.1590/1984-0462/2020/38/2019031.
  6. Bagchi A, Bagchi AS. Anaemia of chronic disease: current update Muruganathan A, Bansode BR, ed. APICON Medicine Update. 27th ed., New Delhi: Jaypee Brothers; 2017. pp. 441–446.
  7. Weiss G, Schett G. Anaemia in inflammatory rheumatic diseases. Nat Rev Rheumatol 2013;9(4):205. DOI: 10.1038/nrrheum.2012.183.
  8. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, et al. The european cancer anaemia survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40(15):2293–2306. DOI: 10.1016/j.ejca.2004.06.019.
  9. Bakta IM, Suega K, Dharmayuda TG. Anemia defisiensi besi. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF, et al., ed. Buku Ajar Ilmu Penyakit Dalam. 6th ed., Jakarta: Interna; 2014. pp. 2589–2599.
  10. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet 2016;387(10021):907–916. DOI: 10.1016/S0140-6736(15)60865-0.
  11. Bakta IM. Hematologi Klinik Ringkas. 1st ed. Khastrifah, Purba DL, ed., Jakarta: EGC; 2012.
  12. Miller J. Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med 2013;3(7):a011866. DOI: 10.1101/cshperspect.a011866.
  13. Widiada PA. Iron-deficiency anemia: a review of diagnosis and management. Intisari Sains Medis 2020;11(1):92–96. DOI: 10.15562/ism.v11i1.578.
  14. Liu K, Kaffes A. Iron deficiency anemia: a review of diagnosis, investigation and management. Eur J Gastroenterol Hepatol 2012;24(2):109–116. DOI: 10.1097/MEG.0b013e32834f3140.
  15. Onken JE, Bregman DB, Harrington RA, Morris D, Acs P, Akright B, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 2014;54(2):306–315.
  16. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008;52(5):897–906. DOI: 10.1053/j.ajkd.2008.05.033.
  17. Stoltzfus RJ, Dreyfuss ML. Guidelines for the Use of Iron Supplements to Prevent and Treat Iron Deficiency Anemia. Washington DC: International Life Sciences Institute Press; 1998. p. 14.
  18. Smith J, Brooker S. Impact of hookworm infection and deworming on anaemia in non-pregnant populations: a systematic review. Trop Med Int Heal 2010;15(5):776–795. DOI: 10.1111/j.1365-3156.2010.02542.x.
  19. Chapin J, Giardina PJ. Thalassemia syndromes. In: Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, et al., ed. Hematology: Basic Principles and Practice. 7th ed., Philadelphia: Elsevier; 2017. pp. 546–570.
  20. Mustafa M, Thiru A, Ilzam E, Firdaus H, Sharifa A, Fairrul K, et al. Pathophysiology, clinical manifestations, and carrier detection in thalassemia. IOSR J Dent Med Sci 2016;15(11):122–126.
  21. Borgna-Pignatti C, Galanello R. Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. In: Greer JP, Arber DA, Glader B, List AF, Means Jr RT, Paraskevas F, et al., ed. Wintrobe's Clinical Hematology. 13th ed., Philadelphia: Lippincott Williams and Wilkins; 2013. pp. 862–913.
  22. Farashi S, Harteveld CL. Molecular basis ofα-thalassemia. Blood Cells, Mol Dis 2017;70:43–53. DOI: 10.1016/j.bcmd.2017.09.004.
  23. Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Thalasemia. HK.01.07/MENKES/1/2018 Indonesia; 2018.
  24. Peters M, Heijboer H, Smiers F, Giordano P. Diagnosis and management of thalassaemia. BMJ 2012;344(jan25 4):e228. DOI: 10.1136/bmj.e228.
  25. Origa R. β-Thalassemia. Genet Med 2017;19(6):609–619. DOI: 10.1038/gim.2016.173.
  26. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010;5(11):1–15. DOI: 10.1186/1750-1172-5-11.
  27. Brancaleoni V, Pierro EDi, Motta I, Cappellini MD. Laboratory diagnosis of thalassemia. Int J Lab Hematol 2016;38(S1):32–40. DOI: 10.1111/ijlh.12527.
  28. Muncie JrHL, Campbell JS. Alpha and beta thalassemia. Am Fam Physician 2009;80(4):339–344.
  29. Higgs D, Engel J, Stamatoyannopoulos G. Thalassemia. Lancet 2012;379(9813):373–383. DOI: 10.1016/S0140-6736(11)60283-3.
  30. Munkongdee T, Chen P, Winichagoon P, Fucharoen S, Paiboonsukwong K. Update in laboratory diagnosis of thalassemia. Front Mol Biosci 2020;7(74):1–12.
  31. Sabath D. Molecular diagnosis of thalassemias and hemoglobinopathies: an ACLPS critical review. Am J Clin Pathol 2017;148(1):6–15. DOI: 10.1093/ajcp/aqx047.
  32. Old J, Henderson S. Molecular diagnostics for haemoglobinopathies. Expert Opin Med Diagn 2010;4(3):225–240. DOI: 10.1517/17530051003709729.
  33. Langhi D, Ubiali EMA, Marques JFC, Verissimo MA, Loggetto SR, Silvinato A, et al. Guidelines on beta-thalassemia major – regular blood transfusion therapy: associacão brasileira de hematologia, hemoterapia e terapia celular: project guidelines: associacão médica brasileira – 2016. Rev Bras Hematol Hemoter 2016;38(4):341–345. DOI: 10.1016/j.bjhh.2016.09.003.
  34. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood 2011;118(13):3479–3483. DOI: 10.1182/blood-2010-08-300335.
  35. Modawi FS, Matar AA, Mofareh AS, Alfadul AFA, Mojeer AS, Saeed ALR, et al. Thalassemia diagnoses and management. EC Microbiol 2017;11(1):27–34.
  36. Kontoghiorghes GJ, Kontoghiorghe CN. Iron and chelation in biochemistry and medicine: new approaches to controlling iron metabolism and treating related diseases. Cells 2020;9(1456):1–43. DOI: 10.3390/cells9061456.
  37. Northern California Comprehensive Thalassemia Center. Standards of Care Guidelines for Thalassemia. California: Children's Hospitel and Research Center Oakland; 2012. pp. 4–9.
  38. Cappellini M, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the Management of Transfusion Transfusion Dependent Thalassemia (TDT). Nicosia: Thalassaemia International Federation; 2014. pp. 42–97.
  39. Borgna-Pignatti C, Marsella M. Iron chelation in thalassemia major. Clin Ther 2015;37(12):2866–2877. DOI: 10.1016/j.clinthera.2015.10.001.
  40. Shirzadfar H, Mokhtari N. Critical review on thalassemia: types, symptoms and treatment. Adv Bioequivalence Bioavailab 2018;1(2):15–18.
  41. Saliba AN, Taher ARHAT. Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med 2015;6:197–209. DOI: 10.2147/JBM.S72463.
  42. Weiss G, Goodnough L. Anemia of chronic disease. N Engl J Med 2005;352(10):1011–1023. DOI: 10.1056/NEJMra041809.
  43. Poggiali E, De Amicis MM, Motta I. Anemia of chronic disease: a unique defect of iron recycling for many different chronic diseases. Eur J Intern Med 2014;25(1):12–17. DOI: 10.1016/j.ejim.2013.07.011.
  44. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 2005;106(6):2196–2199. DOI: 10.1182/blood-2005-04-1766.
  45. Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 2005;104(4):1797–1802. DOI: 10.1182/blood-2004-08-3375.
  46. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005;1(3):191–200. DOI: 10.1016/j.cmet.2005.01.003.
  47. Gangat N, Wolanskyj AP. Anemia of chronic disease. Semin Hematol 2013;50(3):232–238. DOI: 10.1053/j.seminhematol.2013.06.006.
  48. Cullis J. Anaemia of chronic disease. Clin Med (Northfield Il) 2013;13(2):192–196. DOI: 10.7861/clinmedicine.13-2-193.
  49. Thomas C, Kobold U, Thomas L. Serum hepcidin-25 in comparison to biochemical markers and hematological indices for the differentiation of iron restricted erythroporesis. Clin Chem Lab Med 2011;49(2):207. DOI: 10.1515/CCLM.2011.056.
  50. Fraenkel PG. Understanding anemia of chronic disease. Hematol Am Soc Hematol Educ Progr 2015;2015(1):14–18. DOI: 10.1182/asheducation-2015.1.14.
  51. Wicinski M, Liczner G, Cadelski K, Kołnierzak T, Nowaczewska M, Malinowski B. Anemia of chronic diseases: wider diagnostics—better treatment? Nutrients 2020;12(6):1784. DOI: 10.3390/nu12061784.
  52. Cullis J. Diagnosis and management of anemia of chronic disease: current status. Br J Haematol 2011;154(3):289–300. DOI: 10.1111/j.1365-2141.2011.08741.x.
  53. Madu A, Ughasoro M. Anaemia of chronic disease: an in-depth review. Med Princ Pr 2017;26(1):1–9. DOI: 10.1159/000452104.
  54. Ganz T. Anemia of chronic disease. In: Provan D, Gribben J, ed. Molecular Hematology. 4th ed., London: John Wiley & Sons, Ltd; 2019. pp. 155–160.
  55. Chatterjee S, Wetterslev J, Sharma A, Lichstein E, Mukherjee D. Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis. JAMA 2013;173(2):132.
  56. Kidney Disease Improving Global Outcome. Use of ESAs and other agents to treat anemia in CKD. Kidney Int Suppl 2012;2(4):299–310. DOI: 10.1038/kisup.2012.35.
  57. Hardin S. Anemia of chronic disease, older adults, and medicare. J Gerontol Nurs 2010;36(10):3–4. DOI: 10.3928/00989134-20100831-04.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.